Cargando…
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
ESSENTIALS: An antidote for apixaban is not yet available. We tested the effect of different haemostatic agents to reverse the apixaban effect in vitro. Activated prothrombin complex concentrate (aPCC) was superior to prothrombin complex concentrate and recombinant activated factor VII. Even low dos...
Autores principales: | Schultz, Nina H., Tran, Hoa T. T., Bjørnsen, Stine, Henriksson, Carola E., Sandset, Per M., Holme, Pål A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058213/ https://www.ncbi.nlm.nih.gov/pubmed/30046673 http://dx.doi.org/10.1002/rth2.12015 |
Ejemplares similares
-
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017) -
Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015) -
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018) -
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021) -
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)